Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jun 24 · below the Ichimoku cloud · RSI 44 · MACD below its signal
| 2.98 | 52-week high | +131.01% |
| 1.70 | Previous month high | +31.78% |
| 1.46 | R3 (classic) | +12.92% |
| 1.43 | Previous week high | +10.85% |
| 1.40 | R2 (classic) | +8.79% |
| 1.35 | Previous day high | +4.65% |
| 1.32 | R1 (classic) | +2.07% |
| 1.29 | Price now | |
| 1.27 | Previous month low | −1.55% |
| 1.26 | Pivot | −2.07% |
| 1.22 | Previous week low | −5.43% |
| 1.21 | Previous day low | −6.20% |
| 1.18 | S1 (classic) | −8.79% |
| 1.12 | S2 (classic) | −12.92% |
| 1.04 | S3 (classic) | −19.64% |
| 0.9600 | 52-week low | −25.58% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $93.8K | 0.00% | 41.50K | −79% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a CDXS trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 11, 2026 | Erbez Georgia LChief Financial Officer | Sale at price 1.36 per share. | 6.3K | $8.62K |
| Oct 11, 2026 | Moore AlisonChief Executive Officer | Sale at price 1.36 per share. | 6.3K | $8.62K |
| Jun 10, 2026 | De Vre RaymondDirector | Sale at price 2.37 per share. | 2.6K | $6.17K |
| Feb 23, 2026 | Lutz StefanOfficer | Sale at price 1.13 per share. | 5.9K | $6.64K |
| Feb 5, 2026 | Erbez Georgia LChief Financial Officer | Sale at price 1.31 per share. | 3.8K | $5.00K |
| Feb 5, 2026 | Moore AlisonChief Executive Officer | Sale at price 1.31 per share. | 3.8K | $5.00K |
| Feb 5, 2026 | Lutz StefanOfficer | Sale at price 1.31 per share. | 2.5K | $3.26K |
| Jan 6, 2026 | Lutz StefanOfficer | Sale at price 1.70 per share. | 4.7K | $7.95K |
| Nov 30, 2025 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Sale at price 1.67 - 1.75 per share. | 514.3K | $877.85K |
| Nov 30, 2025 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Sale at price 1.67 - 1.75 per share. | 514.3K | $877.85K |
| Nov 20, 2025 | Wolf Dennis PDirector | Sale at price 1.56 per share. | 9K | $13.99K |
| Nov 12, 2025 | Moore AlisonChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 85K | — |
| Nov 11, 2025 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Sale at price 1.94 - 1.96 per share. | 1.08M | $2.10M |
| Nov 10, 2025 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Sale at price 1.70 - 1.80 per share. | 1.06M | $1.87M |
| Nov 10, 2025 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Sale at price 1.70 - 1.80 per share. | 1.06M | $1.87M |
| Nov 10, 2025 | De Vre RaymondDirector | Sale at price 1.74 per share. | 1.4K | $2.46K |
| Nov 10, 2025 | Dilly Stephen GeorgeDirector | Stock Award(Grant) at price 1.85 per share. | 50K | $92.36K |
| Oct 12, 2025 | Erbez Georgia LChief Financial Officer | Sale at price 2.50 per share. | 6.2K | $15.63K |
| Oct 12, 2025 | Moore AlisonChief Technology Officer | Sale at price 2.51 per share. | 6.2K | $15.63K |
| Aug 3, 2025 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 2.68 - 2.84 per share. | 85K | $227.92K |
TimeframesThe daily, weekly and monthly trends are down; the hourly is steadying, a bounce inside them.
bouncing over the 21 EMA
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -23.9 | -18.5 | 61.4 | 73.0 | -1.8 | -18.4 | -38.1 | 21.4 | -18.2 | -7.2 | −20.9% | ||
| 2025 | -12.2 | -27.4 | -11.5 | -14.5 | 0.0 | 6.1 | 9.8 | 1.9 | -10.6 | -2.9 | -27.0 | -5.8 | −65.8% |
| 2024 | -13.8 | 76.8 | -24.9 | -16.6 | 16.2 | -8.3 | 15.5 | -19.3 | 6.6 | 1.9 | 45.9 | 4.1 | +56.4% |
| 2023 | 32.0 | -21.3 | -14.5 | -5.3 | -43.6 | 26.7 | 28.6 | -51.7 | 8.6 | -12.2 | 42.2 | 29.2 | −34.5% |
| 2022 | -34.4 | -2.8 | 3.5 | -41.7 | -11.2 | -2.1 | -34.4 | 2.2 | -13.6 | -7.3 | -2.7 | -14.8 | −85.1% |
| 2021 | 6.7 | -5.1 | 3.5 | 1.3 | -11.6 | 10.5 | -6.6 | 27.7 | -13.9 | 49.5 | -0.2 | -9.9 | +43.2% |
| 2020 | -1.9 | -25.7 | -4.2 | 4.0 | 7.0 | -8.2 | 3.8 | 16.7 | -14.9 | 13.4 | 39.1 | 17.9 | +36.5% |
| 2019 | 12.7 | 14.9 | -5.0 | -4.0 | -8.1 | 1.8 | -0.3 | -23.6 | -2.2 | -1.5 | 14.9 | 2.9 | −4.3% |
| 2018 | 3.0 | 11.0 | 15.2 | 2.3 | 33.3 | -4.0 | 0.0 | 19.4 | -0.3 | -9.2 | 40.8 | -23.8 | +100.0% |
| 2017 | 3.3 | -13.7 | 17.1 | -8.3 | -9.1 | 36.2 | -0.9 | 2.8 | 19.8 | -7.5 | 12.2 | 21.0 | +81.5% |
| 2016 | -4.3 | 0.2 | -23.4 | 1.3 | 20.6 | 6.1 | 7.9 | -4.1 | 6.5 | 13.7 | -5.9 | -3.2 | +8.7% |
| 2015 | 51.6 | -7.6 | 29.2 | -3.9 | -5.5 | -6.0 | -16.5 | 14.8 | -9.1 | -4.1 | 17.5 | 10.7 | +67.9% |
| 2014 | 33.6 | -0.5 | 9.7 | -16.7 | -15.9 | 2.1 | 43.8 | 21.0 | -8.3 | 9.9 | -12.1 | 12.0 | +80.0% |
| 2013 | 7.2 | -12.7 | 15.5 | -6.3 | 2.7 | -3.9 | 10.9 | -29.8 | 2.3 | -1.1 | -13.8 | -6.7 | −36.7% |
| 2012 | 5.1 | -29.3 | -7.4 | -0.8 | -13.8 | 18.9 | -17.0 | -26.3 | 33.5 | -14.2 | -17.7 | 3.3 | −58.3% |
| 2011 | -14.8 | 18.1 | 10.9 | -11.3 | 4.4 | -12.1 | -6.5 | -27.9 | -29.6 | 0.9 | 4.6 | 10.0 | −50.0% |
| 2010 | -24.1 | -15.3 | 2.2 | -9.4 | 18.4 | 6.7 | -8.0 | 12.5 | −22.2% |
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Buy / hold / sell counts